WO2008099083A3 - Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives - Google Patents

Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives Download PDF

Info

Publication number
WO2008099083A3
WO2008099083A3 PCT/FR2008/000014 FR2008000014W WO2008099083A3 WO 2008099083 A3 WO2008099083 A3 WO 2008099083A3 FR 2008000014 W FR2008000014 W FR 2008000014W WO 2008099083 A3 WO2008099083 A3 WO 2008099083A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
treating neurodegenerative
neuroprotective compounds
obtaining drugs
drugs
Prior art date
Application number
PCT/FR2008/000014
Other languages
English (en)
Other versions
WO2008099083A2 (fr
Inventor
Ridant Alain Le
Catherine Harpey
Original Assignee
Servier Lab
Ridant Alain Le
Catherine Harpey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Ridant Alain Le, Catherine Harpey filed Critical Servier Lab
Priority to AU2008214550A priority Critical patent/AU2008214550A1/en
Priority to CA002674100A priority patent/CA2674100A1/fr
Priority to JP2009544434A priority patent/JP2010514827A/ja
Priority to BRPI0806275-7A priority patent/BRPI0806275A2/pt
Priority to US12/448,719 priority patent/US20090298813A1/en
Priority to CNA2008800017537A priority patent/CN101578100A/zh
Priority to KR1020097016380A priority patent/KR20090104853A/ko
Priority to EA200900923A priority patent/EA200900923A1/ru
Priority to EP08761738A priority patent/EP2101768A2/fr
Priority to MX2009007198A priority patent/MX2009007198A/es
Publication of WO2008099083A2 publication Critical patent/WO2008099083A2/fr
Publication of WO2008099083A3 publication Critical patent/WO2008099083A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Utilisation de composés neuroprotecteurs pour l'obtention de médicaments destinés au traitement curatif des maladies neurodégénératives et/ou à la prévention de l'apparition des troubles découlant de ces maladies.
PCT/FR2008/000014 2007-01-05 2008-01-04 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives WO2008099083A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2008214550A AU2008214550A1 (en) 2007-01-05 2008-01-04 Use of neuroprotective compounds for obtaining drugs for treating neurodegenerative diseases
CA002674100A CA2674100A1 (fr) 2007-01-05 2008-01-04 Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives
JP2009544434A JP2010514827A (ja) 2007-01-05 2008-01-04 神経変性疾患を処置するための薬剤を得るための神経保護化合物の使用
BRPI0806275-7A BRPI0806275A2 (pt) 2007-01-05 2008-01-04 utilização de compostos neuroprotetores para a obtenção de medicamentos destinados ao tratamento de doenças neurodegenerativas
US12/448,719 US20090298813A1 (en) 2007-01-05 2008-01-04 Use of neuroprotective compounds in obtaining medicaments intended for the treatment of neurodegenerating diseases
CNA2008800017537A CN101578100A (zh) 2007-01-05 2008-01-04 神经保护性化合物在制备用于治疗神经变性疾病的药物中的用途
KR1020097016380A KR20090104853A (ko) 2007-01-05 2008-01-04 신경퇴행성 질환을 치료하는 약물을 수득하기 위한 신경보호 화합물의 용도
EA200900923A EA200900923A1 (ru) 2007-01-05 2008-01-04 Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
EP08761738A EP2101768A2 (fr) 2007-01-05 2008-01-04 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives
MX2009007198A MX2009007198A (es) 2007-01-05 2008-01-04 Uso de compuestos neuroprotectores para obtener medicamentos destinados al tratamiento de enfermedades neurodegenerativas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0700048A FR2911143A1 (fr) 2007-01-05 2007-01-05 Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.
FR0700048 2007-01-05

Publications (2)

Publication Number Publication Date
WO2008099083A2 WO2008099083A2 (fr) 2008-08-21
WO2008099083A3 true WO2008099083A3 (fr) 2008-12-11

Family

ID=38309971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000014 WO2008099083A2 (fr) 2007-01-05 2008-01-04 Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives

Country Status (14)

Country Link
US (1) US20090298813A1 (fr)
EP (1) EP2101768A2 (fr)
JP (1) JP2010514827A (fr)
KR (1) KR20090104853A (fr)
CN (1) CN101578100A (fr)
AR (1) AR064749A1 (fr)
AU (1) AU2008214550A1 (fr)
BR (1) BRPI0806275A2 (fr)
CA (1) CA2674100A1 (fr)
EA (1) EA200900923A1 (fr)
FR (1) FR2911143A1 (fr)
MA (1) MA31032B1 (fr)
MX (1) MX2009007198A (fr)
WO (1) WO2008099083A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926077A1 (fr) * 2008-01-04 2009-07-10 Servier Lab Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP6154282B2 (ja) * 2013-10-03 2017-06-28 株式会社ファンケル 神経幹細胞又は神経前駆細胞の増殖促進剤
CN111018802B (zh) * 2019-12-03 2021-07-06 湖北大学 具有抗帕金森氏症的化合物、制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000319A1 (fr) * 1977-11-25 1979-06-14 Buzas Andre Nouvelles indolo (2, 3-a) quinolizidines, leur preparation et leur utilisation therapeutique
EP0658557A1 (fr) * 1993-12-14 1995-06-21 Adir Et Compagnie Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP1470818A1 (fr) * 2003-04-25 2004-10-27 Neuro3D Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1566099A (zh) * 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000319A1 (fr) * 1977-11-25 1979-06-14 Buzas Andre Nouvelles indolo (2, 3-a) quinolizidines, leur preparation et leur utilisation therapeutique
EP0658557A1 (fr) * 1993-12-14 1995-06-21 Adir Et Compagnie Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP1470818A1 (fr) * 2003-04-25 2004-10-27 Neuro3D Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP

Also Published As

Publication number Publication date
CA2674100A1 (fr) 2008-08-21
WO2008099083A2 (fr) 2008-08-21
FR2911143A1 (fr) 2008-07-11
KR20090104853A (ko) 2009-10-06
EA200900923A1 (ru) 2009-12-30
AR064749A1 (es) 2009-04-22
CN101578100A (zh) 2009-11-11
BRPI0806275A2 (pt) 2011-09-06
JP2010514827A (ja) 2010-05-06
MX2009007198A (es) 2009-08-12
AU2008214550A1 (en) 2008-08-21
EP2101768A2 (fr) 2009-09-23
MA31032B1 (fr) 2009-12-01
US20090298813A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
EP2318005A4 (fr) Agents neuroprotecteurs pour la prévention et le traitement de maladies neurodégénératives
HK1224200A1 (zh) 用於治療胰腺癌的藥物
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
EP2166837A4 (fr) Combinaison médicamenteuse utilisable pour le traitement de troubles cutanés
WO2007150077A8 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prévention, du traitement et du diagnostic du cancer
ZA200810531B (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
EP2061503A4 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques pour la prévention, le traitement et le diagnostic du cancer
TNSN08400A1 (en) Organic compounds and their uses
EP2099448A4 (fr) Composition pharmaceutique pour le traitement et la prévention de la resténose
EP2421367A4 (fr) Administration d'allantoïne pour le traitement d'une maladie neurodégénérative et d'un traumatisme neurologique
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EP2206714A4 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
EP3685838A4 (fr) Composé pour le traitement ou la prévention de l'obésité ou de maladies liées à l'obésité, et son application
HK1145994A1 (zh) 苦瓜中提取的化合物在製備預防和治療糖尿病和肥胖的藥物中的用途
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
IL201562A0 (en) Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP2001488A4 (fr) Prevention et traitement des cancers et d'autres maladies
IL210386A (en) Indole history, their medicinal preparations, and their use in the preparation of drugs for the treatment or prevention of neurodegenerative diseases
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
EP2231146A4 (fr) Composition pharmaceutique pour le traitement et la prévention du glaucome
EP2328877A4 (fr) Composés de 1,4-benzoxazine, et dérivés de ceux-ci en tant que médicaments thérapeutiques pour le traitement de troubles neurodégénératifs
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques
WO2008099083A3 (fr) Utilisation de composes neuroprotecteurs pour l'obtention de médicaments destines au traitement de maladies neurodegeneratives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880001753.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08761738

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008214550

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008761738

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2674100

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4319/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12448719

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 578125

Country of ref document: NZ

Ref document number: MX/A/2009/007198

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009544434

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009071037

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008214550

Country of ref document: AU

Date of ref document: 20080104

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11389

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 200900923

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020097016380

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0806275

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090706